Effect of zinc-reversible growth-inhibitory activity in human empyema fluid on antibiotic microbicidal activity

Antimicrobial Agents and Chemotherapy

Volumn 44, Issue 1, 2000, Pages 139-142

  Sohnle, Peter G ^a   Hahn, Beth L ^b  

^a CLEMENT J ZABLOCKI VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; BINDING PROTEIN; CALPROTECTIN; CEFAZOLIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SODIUM CHLORIDE; TROVAFLOXACIN; ZINC;

ABSCESS; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL GROWTH; CASE REPORT; CONCENTRATION RESPONSE; CONTROLLED STUDY; EMPYEMA; ESCHERICHIA COLI; GROWTH INHIBITION; HUMAN; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS;

EID: 0033989549     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.44.1.139-142.2000     Document Type: Article

References (26)

1. Bamberger, D. M., K. M. Bettin, and D. N. Gerding. 1987. Neutrophil localization in acute and chronic experimental abscesses. J. Lab. Clin. Med. 109:389-395.
2. Bamberger, D. M., and B. L. Herndon. 1990. Bactericidal capacity of neutrophils in rabbits with experimental acute and chronic abscesses. J. Infect. Dis. 162:186-192.
3. Bamberger, D. M., B. L. Herndon, and P. R. Suvarna. 1993. The effect of zinc on microbial growth and bacterial killing by cefazolin in a Staphylococcus aureus abscess milieu. J. Infect. Dis. 168:893-896.
4. Bryant, R. E., and J. A. Mazza. 1989. Effect of the abscess environment on the antimicrobial activity of ciprofloxacin. Am. J. Med. 87(Suppl. 5A):23S-27S.
5. Clohessy, P. A., and B. E. Golden. 1995. Calprotectin-mediated zinc chelation as a biostatic mechanism in host defence. Scand. J. Immunol. 42:551-556.
6. Fagerhol, M. K., K. B. Andersson, C. F. Naess-Andresen, P. Brandtzaeg, and I. Dale. 1990. Calprotectin (the L1 protein), p. 187-210. In V. L. Smith and J. R. Dedman (ed.), Stimulus response coupling: the role of intracellular calcium-binding proteins. CRC Press, Boca Raton, Fla.
7. Finkelstein, R. A., C. V. Sciortino, and M. A. McIntosh. 1983. Role of iron in microbe-host interactions. Rev. Infect. Dis. 5:S759-S777.
8. Girard, A. E., D. Girard, T. D. Gootz, J. A. Faiella, and C. R. Cimochowski. 1995. In vivo efficacy of trovofloxacin (CP-99,219), a new quinolone with extended activities against gram-positive pathogens, Streptococcus pneumonia, and Bacteroides fragilis. Antimicrob. Agents Chemother. 39:2210-2216.
9. Hindler, J. (ed.). 1992. Antimicrobial susceptibility testing, p. 5.0.1-5.25.1. In H. D. Isenberg (ed.), Clinical microbiology procedures handbook. American Society for Microbiology, Washington, D.C.
10. Kenny, P. A., L. K. Spencer, P. J. McDonald, and J. J. Finlay-Jones. 1990. Functional activity of individual abscess neutrophils from mice. Infect. Immun. 58:4004-4010.
11. Lepper, M. H., and H. F. Dowling. 1951. Treatment of pneumococcic meningitis with penicillin compared with penicillin plus aureomycin. Arch. Intern. Med. 88:489-496.
12. McNamara, M. P., J. H. Wiessner, C. Collins-Lech, B. L. Hahn, and P. G. Sohnle. 1988. Neutrophil death as a defense mechanism against Candida albicans infections. Lancet ii:1163-1165.
13. Miyasaki, K. T., A. L. Bodeau, A. R. K. Murthy, and R. I. Lehrer. 1993. In vitro antimicrobial activity of the human neutrophil cytosolic S-100 protein complex, calprotectin, against Capnocytophaga sputigena. J. Dent. Res. 72: 517-523.
14. Polk, H. C., Jr., and D. E. Fry. 1981. Infection and fever in the surgical patient, p. 1-19. In J. D. Hardy, (ed.), Complications in surgery and their management. W. B. Saunders, Philadelphia, Pa.
15. Santhanagopalan, V., B. L. Hahn, B. Dunn, J. H. Wiessner, and P. G. Sohnle. 1995. Antimicrobial activity of calprotectin isolated from human empyema fluid supernatants. Clin. Immunol. Immunopathol. 76:285-290.
16. Santhanagopalan, V., B. L. Hahn, and P. G. Sohnle. 1995. Resistance of zinc-supplemented Candida albicans yeast cells to the growth-inhibitory effect of calprotectin. J. Infect. Dis. 171:1289-1294.
17. Sohnle, P. G. 1997. Antimicrobial defence through competition for zinc. Rev. Med. Microbiol. 8:217-224.
18. Sohnle, P. G., C. Collins-Lech, and J. H. Wiessner. 1991. Antimicrobial activity of an abundant calcium-binding protein in the cytoplasm of human neutrophils. J. Infect. Dis. 163:187-192.
19. Sohnle, P. G., C. Collins-Lech, and J. H. Wiessner. 1991. The zinc-reversible antimicrobial activity of neutrophil lysates and abscess fluid supernatants. J. Infect. Dis. 164:137-142.
20. Sohnle, P. G., B. L. Hahn, and V. Santhanagopalan. 1996. Inhibition of Candida albicans growth by calprotectin in the absence of direct contact with the organisms. J. Infect. Dis. 174:1369-1372.
21. Steinbakk, M., C. F. Naess-Andresen, E. Lingass, I. Dale, P. Brandtzaeg, and M. K. Fagerhol. 1990. Antimicrobial actions of calcium binding leucocyte L1 protein, calprotectin. Lancet 336:763-765.
22. Stevens, D. L., A. E. Gibbons, R. Bergstrom, and V. Winn. 1988. The Eagle effect revisited - efficacy of clindamycin, erythromycin, and penicillin in the treatment of streptococcal myositis. J. Infect. Dis. 158:23-28.
23. Stevens, D. L., M. H. Tanner, J. Winship, R. Swarts, K. M. Ries, P. M. Schlievert, and E. Kaplan. 1989. Reappearance of scarlet fever toxin A among streptococci in the Rocky Mountain West - severe group A streptococcal infections associated with a toxic shock-like syndrome. N. Engl. J. Med. 321:1-7.
24. Stevens, D. L., S. Yan, and A. E. Bryant. 1993. Penicillin-binding protein expression at different growth stages determines penicillin efficacy in vitro and in vivo - an explanation for the inoculum effect. J. Infect. Dis. 167:1401-1405.
25. Weinberg, E. D. 1975. Nutritional immunity - host's attempt to withhold iron from microbial invaders. JAMA 231:39-41.
26. Zeiler, H. J., and K. Grohe. 1984. The in vitro and in vivo activity of ciprofloxacin. Eur. J. Clin. Microbiol. 3:339-343.